Trial Information

Summary: Evalation of the Efficacy of the NK1 Antagonist GR205171 in Post Traumatic Stress Disorder

This is a 10-week, double-blind, placebo-controlled trial of an investigational medication in the treatment of post traumatic stress disorder.

People with PTSD between the ages of 18 and 65 may be eligible for this study. Potential participants receive a thorough psychiatric and medical screening, and if found eligible, enter into the 10-week trial. Participants must be free of psychotropic medications for at least 2 weeks prior to the beginning of the 10 weeks. There are weekly in-person visits throughout the study, where study physicians evaluate the participant's progress and monitor the occurrence of side effects, and participants have blood drawn for safety lab tests.

Participants have the option of undergoing an MRI and lumbar puncture both during the first 2 weeks of the study and at the end of the 2 weeks.

Compensation Provided

Patient Inclusion/Exclusion Criteria:

Males and females between the ages of 18-65 with a primary diagnosis of post-traumatic stress disorder

Current psychiatric medication, major unstable medical conditions, hepatitis B,C, or any liver impairment, current or recent substance abuse or dependence, pregnancy or lactation in females, and current participation in structured psychotherapy

If you would like to learn more about participating in this study, please send an e-mail message using the form below.